Quantcast
Home > Quotes > MRTX
MRTX

Mirati Therapeutics, Inc. Common Stock (MRTX) Quote & Summary Data

$75.55
*  
4.81
6.8%
Get MRTX Alerts
*Delayed - data as of May 21, 2019  -  Find a broker to begin trading MRTX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    MRTX After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 71.92 / $ 79.34
1 Year Target
77
Today's High / Low
$ 75.71 / $ 71
Share Volume
525,826
50 Day Avg. Daily Volume
638,649
Previous Close
$ 70.74
52 Week High / Low
$ 80 / $ 28.50
Market Cap
2,723,360,445
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -3.83
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.93

Intraday Chart

Shares Traded

Share Volume:
525,826
50 Day Avg. Daily Volume:
638,649

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.83

Trading Range

The current last sale of $75.55 is 165.09% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 75.71 $ 80
 Low: $ 71 $ 28.50

ETFs with MRTX as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
5.78% Invesco DWA Healthcare Momentum ETF (PTH) +13.65 (21.01%)
2.8% Invesco DWA NASDAQ Momentum ETF (DWAQ) +18.82 (19.87%)
1.52% Invesco DWA SmallCap Momentum ETF (DWAS) +10.80 (26.95%)
0.4% iShares Microcap ETF (IWC) +14.60 (18.77%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

Mirati Therapeutics, Inc. is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer. Our precision oncology clinical programs utilize genomic testing to identify and select cancer patients who we believe would be most likely to benefit from targeted treatment. In immuno-oncology, we are advancing a clinical program where our product candidate has the potential to improve the immune environment of tumor cells and enhance and expand the efficacy of existing cancer immunotherapy medicines when given in combination. Our KRAS inhibitor program is focused on developing novel inhibitors of KRAS mutations and includes one clinical candidate and a preclinical program. We also have additional preclinical programs which include potentially first-in-class and best-in-class product candidates specifically designed to address mutations and tumors where few treatment options exist.  ... More ...  



Risk Grade

Where does MRTX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 71.37
Open Date:
May 21, 2019
Close Price:
$ 70.74
Close Date:
May 20, 2019


Consensus Recommendation

Analyst Info